1.
Presurgical trial of metformin in overweight and obese patients with newly diagnosed breast cancer.
Kalinsky, K, Crew, KD, Refice, S, Xiao, T, Wang, A, Feldman, SM, Taback, B, Ahmad, A, Cremers, S, Hibshoosh, H, et al
Cancer investigation. 2014;(4):150-7
-
-
Free full text
-
Abstract
INTRODUCTION We conducted a presurgical trial to assess the tissue-related effects of metformin in overweight/obese breast cancer (BC) patients. METHODS Metformin 1,500 mg daily was administered to 35 nondiabetics with stage 0-III BC, body mass index (BMI) ≥ 25 kg/m(2). The primary endpoint was tumor proliferation change (i.e., ki-67). Tumor proliferation change was compared to untreated historical controls, matched by age, BMI, and stage. RESULTS There was no reduction in ln(ki-67) after metformin (p = .98) or compared to controls (p = .47). There was a significant reduction in BMI, cholesterol, and leptin. CONCLUSION Despite no proliferation changes, we observed reductions in other relevant biomarkers.